Omeros Corporation (NASDAQ:OMER) Receives $40.33 Consensus Target Price from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $40.3333.

OMER has been the topic of a number of recent analyst reports. HC Wainwright boosted their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th.

Omeros Price Performance

NASDAQ OMER opened at $11.00 on Wednesday. The firm has a market cap of $779.90 million, a PE ratio of -5.45 and a beta of 2.45. Omeros has a one year low of $2.95 and a one year high of $17.65. The stock’s 50 day simple moving average is $11.71 and its 200 day simple moving average is $9.39.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OMER. State of Wyoming acquired a new position in Omeros during the 4th quarter worth $25,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Omeros in the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Omeros during the fourth quarter worth $33,000. Tower Research Capital LLC TRC raised its position in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 11,971 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in shares of Omeros during the second quarter valued at $40,000. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.